Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Phase 2

Completed

• Conditions: Obesity

• Registration Number: NCT00533481
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2004-02
• Primary Completion: 2004-12
• Study Completion: 2004-12
• Study First Submitted: 2007-09-19
• Study First Submitted QC: 2007-09-19
• Study First Posted: 2007-09-21
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-15
• Last Update Posted: 2016-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 497

Inclusion Criteria

• Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Read More

Exclusion Criteria

• Subject has high blood pressure or is taking any high blood pressure medicine
• History of psychiatric disorder, stroke, or heart disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL